Leishmanial infections are worldwide in distribution, occurring in Africa, North and South America, Southern Europe, and Asia. The clinical manifestations of leishmaniasis are extremely varied and include visceral (VL), cutaneous (CL), diffuse cutaneous, and mucosal (ML) disease. There are an estimated 15-20 million cases of leishmaniasis worldwide and there are neither leishmania vaccines nor standardized tests for diagnosis. The existing treatment is expensive and often requires hospitalization. Notwithstanding, the leishmaniases are excellent candidates for the development of vaccines, antigen-based therapeutics, cytokine therapy, and effective diagnostics. The goal of this project is to develop leishmania recombinant antigens for vaccine development for use in VL. We have developed a vaccine for CL and ML that is now in clinical trials. This vaccine does not appear to be optimized for VL in animal models. There could be two reasons for this; 1) either the antigens or 2) the adjuvant/delivery system are not optimized to induce adequate protection against VL. In this proposal we will address both of these possibilities by identifying T cell antigens of the L. donovani complex, and using new adjuvants, DNA immunization, or combinations (i.e. prime boost protocols) to develop an effective vaccine for humans and dogs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI025038-17
Application #
7082785
Study Section
Special Emphasis Panel (ZRG1-SSS-F (02))
Program Officer
MO, Annie X Y
Project Start
1993-11-01
Project End
2009-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
17
Fiscal Year
2006
Total Cost
$621,488
Indirect Cost
Name
Infectious Disease Research Institute
Department
Type
DUNS #
809846819
City
Seattle
State
WA
Country
United States
Zip Code
98102
Reed, Steven G; Carter, Darrick; Casper, Corey et al. (2018) Correlates of GLA family adjuvants' activities. Semin Immunol 39:22-29
Duthie, Malcolm S; Van Hoeven, Neal; MacMillen, Zachary et al. (2018) Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against Leishmania donovani. Front Immunol 9:2420
Duthie, Malcolm S; Lison, Aurore; Courtenay, Orin (2018) Advances toward Diagnostic Tools for Managing Zoonotic Visceral Leishmaniasis. Trends Parasitol 34:881-890
Duthie, Malcolm S; Reed, Steven G (2017) Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis. Clin Vaccine Immunol 24:
Sato, Camila Massae; Sanchez, Maria Carmen Arroyo; Celeste, Beatriz Julieta et al. (2017) Use of Recombinant Antigens for Sensitive Serodiagnosis of American Tegumentary Leishmaniasis Caused by Different Leishmania Species. J Clin Microbiol 55:495-503
Duthie, Malcolm S; Favila, Michelle; Hofmeyer, Kimberley A et al. (2016) Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis. Vaccine 34:2779-86
Hofmeyer, Kimberly A; Duthie, Malcolm S; Laurance, John D et al. (2016) Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites. Clin Vaccine Immunol 23:785-94
Schaut, Robert G; Grinnage-Pulley, Tara L; Esch, Kevin J et al. (2016) Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant. Vaccine 34:5225-5234
Carter, Darrick; Fox, Christopher B; Day, Tracey A et al. (2016) A structure-function approach to optimizing TLR4 ligands for human vaccines. Clin Transl Immunology 5:e108
Ghosh, Prakash; Bhaskar, Khondaker R H; Hossain, Faria et al. (2016) Evaluation of diagnostic performance of rK28 ELISA using urine for diagnosis of visceral leishmaniasis. Parasit Vectors 9:383

Showing the most recent 10 out of 80 publications